 BIOLASE, Inc. NASDAQ: BIOL, a global leader in dental lasers, announced today the expiration of the Companys rights offering, which was oversubscribed. The subscription period for its previously announced rights offering the Offering of units at a subscription price of 1,000 per unit, consisting of one share of the Companys newly created Series F Convertible Preferred Stock with a face value of 1,000 and immediately convertible at the option of the holder into shares of BIOLASEs common stock at a conversion price of 0.40 per share and 2,500 warrants to purchase BIOLASEs common stock with an exercise price of 0.40 per share, expired on July 15, 2020, and these rights are no longer exercisable. 